A one‑year course of T‑DM1 offers excellent cancer‑free survival for early HER2‑positive breast cancer, with far less nerve ...

Targeted therapies are cancer medications that work more selectively than standard chemotherapy medications. They do this by targeting specific molecules or genetic changes in cancer cells in order to ...

“Designing treatments unique to individual patients has always been the promised goal of personalized medicine. After 25 years the FDA has, for the first time, outlined a framework to facilitate these ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding ...

This episode, titled Positioning Emerging Targeted Therapies in the Evolving IgA Nephropathy Treatment Paradigm, features nephrology experts discussing the following critical question: When are you ...

The American Cancer Society’s Cancer Statistics, 2026 report highlights a historic milestone: the 5-year relative survival rate for all cancers combined has reached 70%, up from 49% in the mid-1970s.

Pharmacists play a vital role in oncology, enhancing patient care through medication management, education, and support for novel therapies.

Lung cancer in never-smokers exhibits distinct biological characteristics, often leading to late-stage diagnoses due to lack of screening. Targeted therapies, guided by molecular testing, offer ...

Targeted therapies are medicines to treat cancer. They work differently than standard chemotherapy. Instead of killing all fast-growing cells or keeping them from dividing, targeted therapies work ...

The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.

IgA nephropathy (IgAN), or Bergers disease, is a kidney condition that occurs when abnormal immunoglobulin A (IgA) antibodies trigger inflammation in the kidneys.Until recently, treatment for IgAN ...